Dear shareholders and prospective shareholders,
June marks the last month of our second fiscal quarter, and with the two acquisitions that were announced in March fully integrated as of the beginning of the quarter, we are looking forward to releasing our Q2 financial results.This will give the market a comprehensive understanding of our financial performance from current operations. We expect these to be available the last week of July.
This month we have met with several new funds, some in person and some via conference call. Introducing the CRH story to new investors continues to be our primary investor relations goal over the summer months, with both the retail and institutional communities receiving outreach and updates.
We held a branch presentation at the Canaccord Genuity Wealth Management office in Vancouver to introduce some Investment Advisors to CRH, and provide an update to those already familiar with the story. Feedback and questions centered on our integration of the anesthesia management business, and how potential future acquisitions might affect top and bottom line financial growth.
We attended two conferences in June, one of which we attend annually, and one of which we attended this year for the first time. Both meetings took place the second week of June, with the American Association of Nurse Practitioners (AANP) starting things off in New Orleans, LA. This conference brings together various specialties of nurse practitioners (NPs) from across the U.S. We have experience training NPs at some of our Partner GI practices, but we had yet to exhibit at this conference. Our participation proved to be successful, with a significant number of attendees seeking information regarding training for themselves, or for the physician(s) they work with at their respective practices.
We then went on to the American College of Gastroenterology’s Eastern Regional Postgraduate Course. The course this year was held in Boston, MA, and, as in previous years, was well worth the time spent there. Not only were we able to exhibit at the meeting itself, but the O’Regan System was also featured during the well-attended “hands-on” session held by the College. As more GIs continue to express interest in hemorrhoid treatment, the more of these sessions we are asked to attend – helping to solidify CRH’s name in the GI community.
Thank you for your continued support, and as always if you have any questions, don’t hesitate to contact me directly.
Director, Investor Relations
CRH Medical Corporation
T: 800.660.2153 x 1030